This question was closed without grading. Reason: No acceptable answer
Dec 16, 2021 18:31
2 yrs ago
23 viewers *
English term
United Kingdom
Going the extra mile for premium results
Native in: French (Variants: Swiss, Belgian, Standard-France, Luxembourgish, Canadian) 
Works in: English to French, French to English
on-therapy
English to French
Medical
Medical: Pharmaceuticals
Bonjour,
Il s'agit de l'évaluation de l'effet d'un médicament.
« While no therapeutic drug ranges have been defined for XXX yet, there is a method of evaluating therapy using plasma drug concentrations to define “on-therapy” ranges.
This has been defined in the literature as the range between the 5th percentile trough concentration and the 95th percentile peak concentration.
If a patient’s plasma drug concentration falls outside this defined range, the drug levels are referred to as “below on-therapy” or “above on-therapy.” »
Quelqu'un est-il déjà tombé sur cette expression ? Comme la fourchette n'est précisément pas la « fourchette thérapeutique », je ne peux pas utiliser des expressions comme infra- et supra-thérapeutique.
Il s'agit de l'évaluation de l'effet d'un médicament.
« While no therapeutic drug ranges have been defined for XXX yet, there is a method of evaluating therapy using plasma drug concentrations to define “on-therapy” ranges.
This has been defined in the literature as the range between the 5th percentile trough concentration and the 95th percentile peak concentration.
If a patient’s plasma drug concentration falls outside this defined range, the drug levels are referred to as “below on-therapy” or “above on-therapy.” »
Quelqu'un est-il déjà tombé sur cette expression ? Comme la fourchette n'est précisément pas la « fourchette thérapeutique », je ne peux pas utiliser des expressions comme infra- et supra-thérapeutique.
Proposed translations
(French)
| 4 -1 | sous treatment |
liz askew
|
References
| possibly useful |
liz askew
|
Proposed translations
-1
1 hr
sous treatment
https://researchportal.unamur.be/en/studentTheses/optimizati...
SummaryDirect oral anticoagulants (DOACs) (i.e dabigatran, rivaroxaban, apixaban and edoxaban) are used for the prevention and treatment of thrombotic events including the treatment and prevention of recurrent venous thromboembolism (VTE) and stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Annually, approximately 10-15 % of these patients will require DOAC interruption before an elective or invasive procedure.Laboratory testing is not recommended routinely, as these drugs have a rapid onset and offset of action, a short half-life, predictable pharmacokinetics and a large on-therapy range.H
Les agents anticoagulants oraux directs (AODs) (dabigatran, rivaroxaban, apixaban et edoxaban) sont utilisés pour la prévention et le traitement des événements thromboemboliques, incluant le traitement et la prévention de la maladie thromboembolique veineuse (MTEV) et la prévention des accidents vasculaires cérébraux chez les patients avec fibrillation auriculaire non valvulaire (FANV). Chaque année, environ 10-15 % des patients vont nécessiter une interruption de leur AOD avant une procédure élective ou invasive. Les tests de laboratoire ne sont pas recommandés en routine, étant donné que ces médicaments ont un temps d’action et un temps d’arrêt rapides, une demi-vie courte, une pharmacocinétique prévisible et un large éventail de concentrations plasmatiques sous traitement.
--------------------------------------------------
Note added at 1 hr (2021-12-16 19:41:50 GMT)
--------------------------------------------------
sorry!
sous traitement
--------------------------------------------------
Note added at 22 hrs (2021-12-17 16:55:04 GMT)
--------------------------------------------------
how about
au cours du traitement?
--------------------------------------------------
Note added at 22 hrs (2021-12-17 16:55:29 GMT)
--------------------------------------------------
https://www.proz.com/kudoz/english-to-spanish/medical/199578...
SummaryDirect oral anticoagulants (DOACs) (i.e dabigatran, rivaroxaban, apixaban and edoxaban) are used for the prevention and treatment of thrombotic events including the treatment and prevention of recurrent venous thromboembolism (VTE) and stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Annually, approximately 10-15 % of these patients will require DOAC interruption before an elective or invasive procedure.Laboratory testing is not recommended routinely, as these drugs have a rapid onset and offset of action, a short half-life, predictable pharmacokinetics and a large on-therapy range.H
Les agents anticoagulants oraux directs (AODs) (dabigatran, rivaroxaban, apixaban et edoxaban) sont utilisés pour la prévention et le traitement des événements thromboemboliques, incluant le traitement et la prévention de la maladie thromboembolique veineuse (MTEV) et la prévention des accidents vasculaires cérébraux chez les patients avec fibrillation auriculaire non valvulaire (FANV). Chaque année, environ 10-15 % des patients vont nécessiter une interruption de leur AOD avant une procédure élective ou invasive. Les tests de laboratoire ne sont pas recommandés en routine, étant donné que ces médicaments ont un temps d’action et un temps d’arrêt rapides, une demi-vie courte, une pharmacocinétique prévisible et un large éventail de concentrations plasmatiques sous traitement.
--------------------------------------------------
Note added at 1 hr (2021-12-16 19:41:50 GMT)
--------------------------------------------------
sorry!
sous traitement
--------------------------------------------------
Note added at 22 hrs (2021-12-17 16:55:04 GMT)
--------------------------------------------------
how about
au cours du traitement?
--------------------------------------------------
Note added at 22 hrs (2021-12-17 16:55:29 GMT)
--------------------------------------------------
https://www.proz.com/kudoz/english-to-spanish/medical/199578...
Peer comment(s):
| disagree |
Lionel-N
: Liz, sous traitement indique banalement que le patient prend le médicament, mais ne tiens pas compte des restrictions imposées ici par l'intervalle de confiance à 95%....
14 hrs
|
|
maybe a duff translation then.
|
Reference comments
48 mins
Reference:
possibly useful
https://www.sciencedirect.com/science/article/pii/S073510971...
Relationships between dabigatran level and the dilute PT, prothrombinase-induced clotting time (PiCT), and activated clotting time (ACT) were each reported in a single study. Both the dilute PT and PiCT evinced a complex nonlinear dose-response curve (17). As with heparin, the ACT proved insensitive to lower concentrations of dabigatran. In an ex vivo study, the ACT was normal in 40% of trough samples despite on-therapy dabigatran levels (25).
(25)E.M. Hawes, A.M. Deal, D. Funk-Adcock, et al.
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels
--------------------------------------------------
Note added at 49 mins (2021-12-16 19:20:34 GMT)
--------------------------------------------------
Measurement and Reversal of the Direct Oral Anticoagulantshttps://www.ncbi.nlm.nih.gov › articles › PMC5296289
by BT Samuelson · 2017 · Cited by 99 — In lieu of therapeutic ranges, we use the concept of “on-therapy range.” We define the on-therapy range for a given DOAC at a given dose as the ...
--------------------------------------------------
Note added at 52 mins (2021-12-16 19:23:30 GMT)
--------------------------------------------------
The on-therapy range in AF patients taking dabigatran 150 mg twice daily for at least one week is 31–443 ng/mL (Table 1).5, 17
--------------------------------------------------
Note added at 56 mins (2021-12-16 19:27:29 GMT)
--------------------------------------------------
doesn't "on-therapy levels" just mean "levels during therapy"
Relationships between dabigatran level and the dilute PT, prothrombinase-induced clotting time (PiCT), and activated clotting time (ACT) were each reported in a single study. Both the dilute PT and PiCT evinced a complex nonlinear dose-response curve (17). As with heparin, the ACT proved insensitive to lower concentrations of dabigatran. In an ex vivo study, the ACT was normal in 40% of trough samples despite on-therapy dabigatran levels (25).
(25)E.M. Hawes, A.M. Deal, D. Funk-Adcock, et al.
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels
--------------------------------------------------
Note added at 49 mins (2021-12-16 19:20:34 GMT)
--------------------------------------------------
Measurement and Reversal of the Direct Oral Anticoagulantshttps://www.ncbi.nlm.nih.gov › articles › PMC5296289
by BT Samuelson · 2017 · Cited by 99 — In lieu of therapeutic ranges, we use the concept of “on-therapy range.” We define the on-therapy range for a given DOAC at a given dose as the ...
--------------------------------------------------
Note added at 52 mins (2021-12-16 19:23:30 GMT)
--------------------------------------------------
The on-therapy range in AF patients taking dabigatran 150 mg twice daily for at least one week is 31–443 ng/mL (Table 1).5, 17
--------------------------------------------------
Note added at 56 mins (2021-12-16 19:27:29 GMT)
--------------------------------------------------
doesn't "on-therapy levels" just mean "levels during therapy"
Discussion
Est-ce que vous avez trouvé une solution?
Présentation de concentrations plasmatiques de référence : les «fenêtres thérapeutiques».
"l’effet thérapeutique favorable survient en général lorsque la concentration plasmatique se situe dans une certaine zone de valeurs." — les «fenêtres thérapeutiques».
Donc:
des concentrations plasmatiques «suprathérapeutiques»
des concentrations «subthérapeutiques»
Eg:
Pour certains médicaments cette fourchette thérapeutique est étroite et peut faire courir un risque de sous-dosage ou de sur-dosage aux patients ...